 This study will evaluate the rate of pathological complete response pCR to the sequential therapy of Doxil, paclitaxel, and cyclophosphamide with concurrent Avastin for patients with locally advanced invasive T2,T3, Nany, M0 breast carcinoma. Also, the study will evaluate the clinical and subclinical cardiotoxic effects of this regimen, assess how feasible and safe the study is. Survival without any progression of disease will also be calculated. 